Op-ed views and opinions expressed are solely those of the author.
Millions of Americans suffer concussions every single year, which can be life-altering. But up to now, there is no cure for the often serious brain injury. For the first time in history, medical science is on track to not only diagnose but also treat concussions, with the combination of an FDA-approved test, new research that reveals its effectiveness, and a new treatment that is currently in human trials.
A new study published in The Lancet Neurology revealed that doctors can now identify biomarkers that predict how someone will recover from a traumatic brain injury. By tracking those biomarkers in the immediate aftermath of any head trauma, doctors will be able to tell if someone has suffered a…
For more information, please visit https://www.InvestorWire.com
This article contains Third-Party Content submitted by a third party author submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee, or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion.
By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://IBN.fm/Disclaimer
InvestorWire is part of the InvestorBrandNetwork